Merck Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival (EFS) in Patients With High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
| Merck & Co. (NYSE: MRK) | Delayed: 144.67 -3.69 (2.49%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $148.36 | 52 Week High | $65.46 | |||
| Open | $147.02 | 52 Week Low | $47.97 | |||
| Day High | $147.62 | P/E | 98.41 | |||
| Day Low | $143.47 | EPS | $1.47 | |||
| Volume | 8,863,391 | |||||
